Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Recent/Upcoming Events
Jun 25, 2024 at 9:10 AM EDT

Presentation Title: Role of glucagon-containing dual and triple agonists in the treatment of obesity and MASH

Speaker: Dr. Scott Harris, Chief Medical Officer, Altimmune

Jun 23, 2024 at 1:45 PM EDT

Presentation Title: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity –A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

Speaker: Louis Aronne, M.D., Professor of Metabolic Research and Professor of Clinical Medicine, Weil Cornell Medical School


btn Events


Investor Contact


Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail